Enclosed
TATVA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Tatva Chintan Pharma Chem reported strong FY2026 results. Standalone revenue grew 35.5% to Rs 4,963 million from Rs 3,664 million in FY2025. Profit after tax surged to Rs 390.82 million from just Rs 3.27 million — an extraordinary recovery from the prior year. Consolidated PAT stood at Rs 420.54 million on revenue of Rs 5,059 million. The Board recommended a final dividend of Rs 2 per share (20% on Rs 10 face value), subject to shareholder approval. The statutory auditor (NDJ & Co.) issued an unmodified opinion on both standalone and consolidated financials. The company appointed M/s. Zarna Thakar & Associates as Cost Auditor and RSM Astute Consultech as Internal Auditor for FY2026-27.
Revenue growth of 35.5% YoY and near-complete reversal of prior-year profit decline signals strong operational recovery. The clean audit opinion and dividend recommendation are positive for investor sentiment.